What is the 13F Pro Quality Score for LEXX?

13F Pro ranks Lexaria Bioscience Corp. (LEXX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LEXX's current score at https://13fpro.ai/research/LEXX (free sign-up required for the full ranking).

Where does 13F Pro source LEXX data?

All Lexaria Bioscience Corp. fundamentals and ownership data come directly from SEC EDGAR. Lexaria Bioscience Corp. files with the SEC under CIK 1348362. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LEXX in?

Lexaria Bioscience Corp. (LEXX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LEXX research updated on 13F Pro?

LEXX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lexaria Bioscience Corp.(LEXX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1348362 LEXX stock profile & AI dashboard →

13F Pro Quality Score

4.6/100

Rank #2,868 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

5.4/100

Profitability

1.0/100

Balance Sheet

0.3/100

Earnings Quality

30.0/100

Free Cash Flow

0.8/100

Institutional Flow

29.6/100

Revenue Scale

0.2/100

Dilution Risk

2.7/100

LEXX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lexaria Bioscience Corp. (LEXX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEXX at 4.6/100 on a 32-signal composite quality model, placing it at rank #2,868 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.2) and balance sheet strength (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Lexaria Bioscience Corp. reports net income of $-2.0M, free cash flow of $-1.6M. Top institutional holders of LEXX by reported 13-F value include Invenomic Capital Management, GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LEXX trades on the Nasdaq exchange and files with the SEC under CIK 1348362. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lexaria Bioscience Corp. directly from SEC EDGAR.

✦

Fun facts about Lexaria Bioscience Corp.

Quirks, history, and lore behind LEXX — the kind of stuff that makes a stock memorable.

1
The Basics
A Canadian biotech company listed on Nasdaq · operates in the drug delivery space · headquartered in British Columbia.
2
The Numbers
A micro-cap with annual revenues in the low single-digit millions — this is a company betting its future on intellectual property, not current sales.
3
The History
Founded in the 2010s, it pivoted its focus toward a proprietary lipid-based oral absorption technology after early-stage exploration of multiple delivery formats.
4
The Secret
Its core platform is designed to make cannabinoids, vitamins, and active compounds absorb far more effectively when swallowed — essentially making pills punch harder.
5
The Lore
The company has licensed its DehydraTECH™ technology to partners in the cannabis and nutraceutical industries, positioning itself as a picks-and-shovels play in a booming wellness market.
6
The Giveaway
Its ticker sounds like a sci-fi sequel, its technology is called DehydraTECH™, and it's making CBD and nicotine hit your bloodstream faster — one patent at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$0.00

Net Income

Q3 2026

$-2.0M

Free Cash Flow

Q3 2026

$-1.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+52.0% YoY

$705.9KFY 2025

FY22 $255.4KFY23 $226.2KFY24 $464.3KFY25 $705.9K

Net Income

-105.4% YoY

$-11.9MFY 2025

FY22 $-7.3MFY23 $-6.7MFY24 $-5.8MFY25 $-11.9M

Operating Income

-106.5% YoY

$-11.9MFY 2025

FY22 $-6.6MFY23 $-6.5MFY24 $-5.8MFY25 $-11.9M

EPS (Diluted)

-40.4% YoY

$-0.66FY 2025

FY22 —FY23 $-1.01FY24 $-0.47FY25 $-0.66

Total Assets

-52.9% YoY

$4.2MFY 2025

FY22 $7.8MFY23 $3.1MFY24 $8.9MFY25 $4.2M

Op. Cash Flow

-110.7% YoY

$-10.5MFY 2025

FY22 $-4.9MFY23 $-5.9MFY24 $-5.0MFY25 $-10.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$705.9K +52.0%	$464.3K +105.2%	$226.2K -11.4%	$255.4K -64.7%	$722.7K +224.7%	$222.6K
Net Income	$-11.9M -105.4%	$-5.8M +13.0%	$-6.7M +8.3%	$-7.3M -80.5%	$-4.0M -198.2%	$4.1M
Operating Income	$-11.9M -106.5%	$-5.8M +12.0%	$-6.5M +1.3%	$-6.6M -16.4%	$-5.7M	—
EPS (Diluted)	$-0.66 -40.4%	$-0.47 +53.5%	$-1.01	—	—	—
Total Assets	$4.2M -52.9%	$8.9M +187.5%	$3.1M -60.6%	$7.8M -41.0%	$13.3M +395.9%	$2.7M
Operating Cash Flow	$-10.5M -110.7%	$-5.0M +15.7%	$-5.9M -20.5%	$-4.9M -22.3%	$-4.0M -32.7%	$-3.0M

Get alerted when LEXX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lexaria Bioscience Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LEXX

Invenomic Capital Management LP
$345.0K442,301 sh
GEODE CAPITAL MANAGEMENT, LLC
$229.5K294,157 sh
VANGUARD CAPITAL MANAGEMENT LLC
$173.4K222,293 sh
TORONTO DOMINION BANK
$109.3K140,013 sh
VANGUARD FIDUCIARY TRUST CO
$73.4K94,166 sh
UBS Group AG
$41.1K52,708 sh
STATE STREET CORP
$30.7K39,301 sh
BlackRock, Inc.
$21.4K27,445 sh
XTX Topco Ltd
$19.6K25,067 sh
Krilogy Financial LLC
$19.4K19,653 sh

Fund	Value	Shares
Invenomic Capital Management LP	$345.0K	442,301
GEODE CAPITAL MANAGEMENT, LLC	$229.5K	294,157
VANGUARD CAPITAL MANAGEMENT LLC	$173.4K	222,293
TORONTO DOMINION BANK	$109.3K	140,013
VANGUARD FIDUCIARY TRUST CO	$73.4K	94,166
UBS Group AG	$41.1K	52,708
STATE STREET CORP	$30.7K	39,301
BlackRock, Inc.	$21.4K	27,445
XTX Topco Ltd	$19.6K	25,067
Krilogy Financial LLC	$19.4K	19,653

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LEXX on your watchlist

Track score changes the day Lexaria Bioscience Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LEXX a good stock to buy?

13F Pro's AI-powered analysis of Lexaria Bioscience Corp. (LEXX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LEXX are available on the LEXX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LEXX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LEXX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lexaria Bioscience Corp.'s investment landscape.